Haviland Kate insider trades
Haviland Kate has filed 24 Form 4s with the SEC that we hold, for BPMC (Chief Executive Officer, Director), Fulcrum Therapeutics, Inc. (FULC) (Director), Bicara Therapeutics Inc. (BCAX) (Director) and Avalyn Pharma Inc. (AVLN) (Director). Across all of them we count 1 purchase worth $48.4K and 23 sales worth $3.8M reported on Form 4. None of these purchases or sales is dated in the last 12 months. The largest single trade was a sale of 16,151 shares of BPMC worth $1.4M, dated 2025-03-05. The first filing on our record is dated 2021-09-15 and the latest 2026-07-02.
BPMC
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-09-13 | S, sale reported on Form 4 | 286 | $28.9K | 2021-09-15 |
| 2021-09-13 | S, sale reported on Form 4 | 28 | $2.8K | 2021-09-15 |
| 2021-09-13 | S, sale reported on Form 4 | 8 | $781 | 2021-09-15 |
| 2021-09-13 | S, sale reported on Form 4 | 261 | $26.1K | 2021-09-15 |
| 2021-09-13 | S, sale reported on Form 4 | 417 | $41.4K | 2021-09-15 |
| 2021-12-13 | S, sale reported on Form 4 | 94 | $9.1K | 2021-12-15 |
| 2021-12-13 | S, sale reported on Form 4 | 411 | $40.1K | 2021-12-15 |
| 2021-12-13 | S, sale reported on Form 4 | 210 | $20.7K | 2021-12-15 |
| 2021-12-13 | S, sale reported on Form 4 | 285 | $28.4K | 2021-12-15 |
| 2022-03-03 | S, sale reported on Form 4 | 1,719 | $103.6K | 2022-03-08 |
| 2022-03-07 | S, sale reported on Form 4 | 1,048 | $58.9K | 2022-03-08 |
| 2022-11-03 | P, purchase reported on Form 4 | 1,100 | $48.4K | 2022-11-07 |
| 2023-03-06 | S, sale reported on Form 4 | 6,428 | $293.9K | 2023-03-08 |
| 2023-03-06 | S, sale reported on Form 4 | 212 | $9.5K | 2023-03-08 |
| 2024-03-07 | S, sale reported on Form 4 | 12,464 | $1.1M | 2024-03-11 |
| 2024-11-29 | S, sale reported on Form 4 | 207 | $20.2K | 2024-12-03 |
| 2024-11-29 | S, sale reported on Form 4 | 1,746 | $168.9K | 2024-12-03 |
| 2024-11-29 | S, sale reported on Form 4 | 400 | $38.2K | 2024-12-03 |
| 2025-01-21 | S, sale reported on Form 4 | 1,446 | $159.4K | 2025-01-23 |
| 2025-03-05 | S, sale reported on Form 4 | 16,151 | $1.4M | 2025-03-07 |
| 2025-04-01 | S, sale reported on Form 4 | 600 | $51.3K | 2025-04-03 |
| 2025-04-01 | S, sale reported on Form 4 | 598 | $51.5K | 2025-04-03 |
| 2025-04-01 | S, sale reported on Form 4 | 1,200 | $104.8K | 2025-04-03 |
| 2025-04-01 | S, sale reported on Form 4 | 100 | $8.9K | 2025-04-03 |
Fulcrum Therapeutics, Inc. (FULC)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Bicara Therapeutics Inc. (BCAX)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Avalyn Pharma Inc. (AVLN)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1663022) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms